KEYNOTE-062 [8] demonstrated that compared with chemotherapy, pembrolizumab monotherapy as first-line therapy produced a non-inferior response in patients with GC having PD-L1 CPS ≥ 1. This evidence concerns the gene CD274 and gastric cancer.